CoChat

Trial of Lixisenatide in Early Parkinson’s Disease

Meissner, Wassilios G., Remy, Philippe, Giordana, Caroline, Maltête, David, Derkinderen, Pascal, Houéto, Jean-Luc, Anheim, Mathieu, Benatru, Isabelle, Boraud, Thomas, Brefel-Courbon, Christine, Carrière, Nicolas, Catala, Hélène, Charif, Mahmoud, Colin, Olivier, Corvol, Jean-Christophe, Damier, Philippe, Dellapina, Estelle, Devos, David, Drapier, Sophie, Fabbri, Margherita, Ferrier, Vanessa, Foubert-Samier, Alexandra, Frismand-Kryloff, Solène, Geny, Christian, Georget, Aurore, Germain, Christine, Grimaldi, Stéphane, Hardy, Clémence, Hopes, Lucie, Krystkowiak, Pierre, Laurens, Brice, Lefaucheur, Romain, Mariani, Louise-Laure, Marques, Ana, Marse, Claire, Ory-Magne, Fabienne, Rigalleau, Vincent, Salhi, Hayet, Saubion, Amandine, Stott, Simon R. W., Thalamas, Claire, Thiriez, Claire, Tir, Mélissa, Wyse, Richard K., Benard, Antoine, Rascol, Olivier · 2024 · New England Journal of Medicine

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent. RESULTS: A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%. CONCLUSIONS: In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2312323

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 30 references

Cited by

See all 369

Metadata

Authors
Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., Carrière, N., Catala, H., Charif, M., Colin, O., Corvol, J.-C., Damier, P., Dellapina, E., Devos, D., Drapier, S., Fabbri, M., Ferrier, V., Foubert-Samier, A., Frismand-Kryloff, S., Geny, C., Georget, A., Germain, C., Grimaldi, S., Hardy, C., Hopes, L., Krystkowiak, P., Laurens, B., Lefaucheur, R., Mariani, L.-L., Marques, A., Marse, C., Ory-Magne, F., Rigalleau, V., Salhi, H., Saubion, A., Stott, S. R. W., Thalamas, C., Thiriez, C., Tir, M., Wyse, R. K., Benard, A., & Rascol, O.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • French Clinical Research Network for Parkinson’s Disease and Movement Disorders (NS-Park/F-CRIN), France
  • Université Côte d'Azur (FR)
  • Inserm (FR)
  • Clinical Investigation Center CIC1436 and Departments of Clinical Pharmacology and Neurosciences, Centre Expert Parkinson, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse, France
  • Université de Bordeaux (FR)
  • French Clinical Research Infrastructure Network (FR)
  • Centre Hospitalier Régional et Universitaire de Nancy (FR)
  • Centre Hospitalier Universitaire Amiens-Picardie (FR)
  • Centre Hospitalier Universitaire de Bordeaux (FR)
  • Cure Parkinson’s, London, UK
  • Centre Hospitalier Universitaire de Caen Normandie (FR)
  • Service d’Information Médicale, Clinical Epidemiology Unit (USMR), CHU Bordeaux, F-33000 Bordeaux, France
Venue
New England Journal of Medicine
Published
2024-04-04
Volume
390
Issue
13
Pages
1176-1185
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4393852482
Cited by
369
References
30
Citations by year
2026: 125 · 2025: 160 · 2024: 83
FWCI
97.99
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
Funders
  • Cure Parkinson’s
  • French Ministry of Health - PHRC-N
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords
lixisenatide, Parkinson's disease, GLP-1 receptor agonists, early-stage Parkinson's disease, MDS-UPDRS III, levodopa equivalent daily dose, nausea, neuroprotection, off-medication state, washout period, subcutaneous administration, anti-inflammatory therapy, neurodegeneration, neuroinflammation
MeSH terms
Glucagon-Like Peptide-2 Receptor, Motor Disorders, Glucagon-Like Peptide-1 Receptor Agonists, Antiparkinson Agents, Double-Blind Method, Persons with Disabilities, Humans, Injections, Subcutaneous, Parkinson Disease, Peptides, Treatment Outcome, Disease Progression, Neuroprotective Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial of Lixisenatide in Early Parkinson’s Disease. https://app.cochat.ai/papers/10.1056/nejmoa2312323
The paper
Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., Carrière, N., Catala, H., Charif, M., Colin, O., Corvol, J.-C., Damier, P., Dellapina, E., Devos, D., Drapier, S., . . . Rascol, O. (2024). Trial of Lixisenatide in Early Parkinson’s Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2312323

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.